Immunocore Holdings Ltd
$ 31.45
0.22%
17 Apr - close price
- Market Cap 1,598,664,000 USD
- Current Price $ 31.45
- High / Low $ 32.00 / 30.94
- Stock P/E N/A
- Book Value 7.52
- EPS -0.71
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.10 %
- 52 Week High 40.71
- 52 Week Low 27.44
About
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.
Analyst Target Price
$63.86
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-06 | 2025-08-07 | 2025-05-06 | 2025-02-26 | 2024-11-05 | 2024-08-08 | 2024-05-08 | 2024-02-28 | 2023-11-07 | 2023-08-10 | 2023-05-10 |
| Reported EPS | -0.6 | -0.0035 | -0.2 | -0.49 | -0.3714 | 0.17 | -0.23 | -0.49 | -32.22 | 4 | -0.37 | -35 |
| Estimated EPS | -0.197 | -0.24 | -0.18 | -0.36 | -0.1594 | -0.35 | -0.48 | -0.36 | -21.74 | -28.92 | -32.1 | -32.19 |
| Surprise | -0.403 | 0.2365 | -0.02 | -0.13 | -0.212 | 0.52 | 0.25 | -0.13 | -10.48 | 32.92 | 31.73 | -2.81 |
| Surprise Percentage | -204.5685% | 98.5417% | -11.1111% | -36.1111% | -132.9987% | 148.5714% | 52.0833% | -36.1111% | -48.2061% | 113.8313% | 98.8474% | -8.7294% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.26 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IMCR
2026-04-17 09:08:56
Massachusetts Financial Services Co. trimmed its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 7.9% in the fourth quarter of the prior year. This reduction involved selling 34,994 shares, leaving them with 407,404 shares valued at approximately $14.14 million. Insider selling also reportedly accelerated, with CEO Bahija Jallal and another insider offloading a combined 19,137 shares, while institutional investors still own a significant portion of the company.
2026-04-17 06:10:37
Immunocore Holdings plc (NASDAQ: IMCR) has announced its 2026 Annual General Meeting (AGM) to be held on May 27, 2026, as a hybrid event in London and online. Shareholders will vote on 10 ordinary resolutions, including the re-appointment of three Class II directors, an advisory say-on-pay vote for executive officers, and the approval of the 2025 U.K. Annual Report and directors’ remuneration report. The board unanimously recommends voting FOR all proposals, which also include ratifying Deloitte LLP as auditors and authorizing limited political donations and expenditures.
2026-04-16 17:39:18
This article provides financial data, specifically EBITDA per share, for Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh (LSX:A2QNWU) on the Lang & Schwarz Exchange. The page appears to be a financial data portal displaying an overview of the company's financials. It notes that the market was closed at the time of viewing.
2026-04-15 12:09:04
H.C. Wainwright maintained a Buy rating and a $100 price target for Immunocore Holdings (NASDAQ:IMCR), citing strong penetration and extended duration of therapy for its drug KIMMTRAK. Despite a recent downgrade by Jefferies due to market size concerns, Immunocore reported 29% revenue growth and holds more cash than debt, supporting its pipeline. The company is expected to release significant clinical data soon, including five-year overall survival data from a Phase 3 trial.
2026-04-15 01:40:11
Immunocore (IMCR) has been upgraded to a "Strong Buy" rating by Zacks Investment Research, moving from a "Buy". This upgrade is based on strong upward estimate revisions for its earnings, following its recent earnings report that topped expectations. The company's stock shows potential for continued growth, trading at a reasonable valuation despite a significant surge over the past year.
2026-04-10 19:09:12
This article analyzes Immunocore Holdings Plc (IMCR), highlighting a prevailing positive sentiment that could extend long-term. It identifies a mid-channel oscillation pattern and presents an exceptional 42.7:1 risk-reward setup targeting a 12.7% gain with minimal risk. The article details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for near, mid, and long-term horizons.
